[Reuters] – U.S. health regulators on Wednesday approved the Johnson & Johnson and Pharmacyclics Inc cancer drug Imbruvica to treat chronic lymphocytic leukemia, a slowly progressing form of blood cancer. The Food and Drug Administration decision marks the second approval recently for the medicine, known chemically as ibrutinib. In November, the drug won U.S. approval to treat a rare and aggressive form of non-Hodgkin lymphoma called mantle cell … [visit site to read more]
- Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer lung cancer drug fails in two large studies
- Merck & Co. Inc. (NYSE:MRK) – FDA panel says Merck’s allergy drug effective
- Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol drug for fat disorder may work, but risky -FDA staff
